HOUSTON - CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, has scheduled a Virtual Analyst & Investor Day for December 11, 2024. The event, set to run from 11:30 AM to 1:00 PM ET, will feature discussions on Glioblastoma Multiforme (GBM), an aggressive brain cancer with limited survival prospects, and the company's drug candidates, including Berubicin.
The management team, including CEO John Climaco and Chief Medical (TASE:PMCN) Officer Sandra Silberman, MD, PhD, will be joined by several Key Opinion Leaders (KOLs) in neuro-oncology. These include Michael Weller, Prof. Dr. med. from Universitatsspital Zurich; Samuel Goldlust, MD, of Saint Luke's Cancer Specialists; and Erin Dunbar, MD, from Piedmont Atlanta Hospital.
The live webcast will offer insights into the company's lead drug candidate, Berubicin, which is notable for being an anthracycline that may cross the blood-brain barrier, a feature not commonly found in this class of drugs. The event will also cover the development and regulatory strategy for the company's second asset, TPI 287.
Interested parties can access the live video webcast via the Events page on the Investors section of the CNS Pharmaceuticals website, with a replay available two hours after the live event for a period of 90 days.
CNS Pharmaceuticals' focus on GBM, a type of brain cancer with an average survival time of 14 to 16 months post-diagnosis, underscores the critical need for new treatments in this area. Berubicin is currently in development for GBM and other serious brain and CNS oncology indications.
The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.